EP10 – Utility of Intraoperative Frozen Section plus Immunohistochemical Staining for Determining the Extent of Thyroidectomy in Patients with Follicular Neoplasm

     

    Lee, Yong Sang1,2; Hong, Soon Won1,3;Kim, Soo Young 1,2; Kim, Seok Mo 1,2; Kim, Bup-Woo1,2;Chang, Hang-Seok1,2; Park, Cheong Soo1,2
    1 Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
    2 Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
    3 Department Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

     

    Background: Follicular neoplasm in preoperative fine-needle aspiration cytology is diagnostic challenges. The purpose of this study was to evaluate the role of frozen section plus immunohistochemical (IHC) staining for determining the extent of thyroidectomy in patients with preoperative fine-needle aspiration cytology result of follicular neoplasm.

    Materials and Methods: Between January 2010 and December 2015, 194 patients who underwent thyroidectomy for follicular neoplasm were enrolled. All lesions diagnosed follicular neoplasm in preoperative cytology were examined by intraoperative frozen section. According to performing the IHC staining, patients were divided in two groups; Group I, conventional frozen section examination without IHC (n=129) and Group II, frozen section plus IHC staining (n=65).

    Results: Clinicopathologic characteristics between two groups were similar. In Group I, 53 patients (41.1%) were diagnosed as defer in frozen section, and 16 (24.6%) were diagnosed as defer in Group II. Reoperation rate was decreased in Group II (1.5%) rather than Group I (9.3%).

    Conclusion: Frozen section plus immunohistochemical staining is of value for determining the extent of thyroidectomy in patients with follicular neoplasm.

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    June 20 – 22, 2019
    Rome, Italy

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts

     

  • WCTC3.5 Steering Committee:

     

    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD